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Abstract
The control of temperature during the acute phase of stroke may be a new therapeutic target that can be applied in all stroke
patients, however therapeutic window or timecourse of the temperature effect is not well established. Our aim is to study the
association between changes in body temperature in the first 72 hours and outcome in patients with ischemic (IS) and
hemorrhagic (ICH) stroke. We prospectively studied 2931 consecutive patients (2468 with IS and 463 with ICH). Temperature
was obtained at admission, and at 24, 48 and 72 hours after admission. Temperature was categorized as low (,36uC), normal
(36–37uC) and high (.37uC). As the main variable, we studied functional outcome at 3 months determined by modified Rankin
Scale. Temperature in stroke patients is higher than in controls, and increases gradually in the first 72 hours after stroke. A
positive correlation between temperature and stroke severity determined by NIHSS was found at 24 and 48 hours, but not at
admissionor72 hours.Inalogisticregressionmodel,hightemperaturewasassociatedwithpooroutcomeat24 hours(OR2.05,
95% CI 1.59–2.64, p,0.0001) and 48 hours (OR 1.93, 95% CI 1.08–2.34, p=0.007), but not at admission or
72 hours. Temperature increases in patients with stroke in the first 72 hours, with the harmful effect of high temperature
occurring inthe first48 hours. Theneuroprotective effectoflow temperature occurswithinthe first 24 hours from strokeonset.
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Introduction
Demographic changes and improvement in quality of health
care systems in Western countries are conditioning an increase in
the incidence and prevalence of ischemic and hemorrhagic
cerebrovascular diseases. These serious consequences, together
with vascular dementia, are expected to increase in the next
decades, with no further options in prevention and treatment
expected in the near future.
The control of vascular risk factors, especially hypertension, and
probably the use of statins remain the most effective preventive
treatments. Pharmacological (intravenous or intra-arterial) or
mechanical reperfusion therapy are the most effective treatments
during the acute phase of ischemic stroke (IS) and are associated
with good outcome in 50–70% of cases [1]. However, it is difficult
to apply these treatments in more than 10% of patients due to the
short therapeutic window. There is currently no effective
treatment for intracerebral hemorrhage (ICH).
The control of body temperature is becoming one the most
promising neuroprotective treatment strategies for acute IS and
ICH. In fact, in animal models of ischemia, reduction of body
temperature has been observed to act as a one of the best
neuroprotective strategies observed to date [2,3].
In agreement with the clear experimentalevidence, it wasobserved
that the control of body temperature during the acute phaseof IS and
ICH is a therapeutic opportunity associated with good outcome in
10–25% of cases [4,5,6,7,8,9,10,11]. However, to date, there is no
clear clinical data in adequately large sample sizes which determine
the effect of temperature, in relation to time, on outcome after
ischemic stroke or hemorrhage [12], or the best moment to induce
the control of temperature with neuroprotective results.
With this objective, in the present clinical study, we have
analyzed and studied the association between changes in body
temperature within the first 72 hours after stroke and the evolution
of brain damage by looking at the inflammatory response and
outcome at 3 months in a large series of patients with IS and ICH.
In addition, we have tried to determine the time window for
starting the control of body temperature.
Methods
Studied population
Since October 2004, we prospectively included all patients with
IS and non-traumatic ICH admitted to the Neurology Depart-
ment of the Hospital Clı ´nico Universitario de Santiago de Compostela in
the BICHUS registry, approved by the Research Ethics Commit-
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analysis of this registry to study the influence of temperature in the
first 72 hours in stroke outcome, and its possible association with
systemic inflammation. Written informed consent was obtained
from each patient or from their relatives after full explanation of
the procedures.
From December 2004 to December 2010, 3873 patients were
included for the analysis. Patients that had transient ischemic
attack (TIA) (312 patients), transferred to other hospitals during
the acute phase (17 patients), died by causes other than vascular
(19 patients), lacked basal temperature registration (209 patients),
lacked inflammatory markers (61 patients) and/or lacked follow-
up at 3 months (375 patients) were excluded. Finally, 2931 patients
(2468 with IS and 463 with ICH) were deemed valid for the
analysis.
Patients were treated according to the Stroke Unit protocol of
the Hospital Clı ´nico Universitario de Santiago de Compostela. All patients
with axillary temperature .37.5uC were treated with metamizol
(2 g intravenous) or paracetamol (500 mg orally) every 6 hours
(although treatment with metamizol and paracetamol were used to
control fever, the condition of hypothermia was not induced in any
of the patients recruited). All non-anticoagulated patients with IS
received 100 mg/day of aspirin or 75 mg/day of clopidogrel if
contraindication to aspirin was present. When reperfusion therapy
was administered, antithrombotic treatment was delayed 24 hours.
In order to obtain a control group we recorded axillary
temperature from 282 relatives of neurological outpatients,
matched by sex and age.
Studied variables
The following basal variables were included in this study: age,
sex, type of stroke, previous history of vascular risk factors, blood
pressure and glucose levels at admission and time from stroke
onset.
In accordance with previous clinical studies [11] and following
the Stroke Unit protocol of our hospital, after drying the armpit,
the axillary temperatures were measured by professional nurses,
after a 5 minute waiting time using mercury in glass thermom-
eters. Temperature was obtained at admission and every 6 hours
during the first 72 hours, which means that temperature was
measured at 2 a.m., 8 a.m., 2 p.m. and 8 p.m. for 72 hours in
every patient. Basal temperature and the highest temperature
reading during the first 24, 48 and 72 hours were considered for
the analysis. Temperature was analyzed as a continuous variable
and categorized into three groups: low (,36uC), normal (36–37uC)
and high temperature (.37uC).
Leukocyte count, fibrinogen, high-sensitive C-reactive protein
(hs-CRP) and erythrocyte sedimentation rate (ESR) were analyzed
as inflammatory variables. Systemic inflammation was considered
present when at least two of the following results were observed:
leukocyte count .10.000/mmc, fibrinogen .500 mg/dL, hs-
CRP .3 mg/L and ESR .20 mm/h.
All patients underwent cranial computed tomography (CT) on
admission. In patients with IS, control CT was obtained at 48–
72 hours. In patients treated with rtPA, control CT was obtained
24 hours after starting treatment. Lesion volume was measured
[13] in control CT in patients with IS and in CT on admission in
patients with ICH.
Stroke subtype was classified according to TOAST criteria [14]
in IS and as hypertensive, amyloid, in relation with antiplatelet/
anticoagulant treatment, secondary to arteriovenous malformation
or others in ICH.
The use of reperfusion therapy, the inclusion in clinical trials
and the presence of infections during the first 72 hours were
considered for the analysis. Certificated neurologists evaluated
neurological deficit at admission, 24, 48 and 72 hours and at 3
months using NIHSS. Functional outcome was evaluated using
modified Rankin Scale (mRS) at 3 months (615 days) considering
mRS ,3 as good outcome and mRS $3 as poor outcome.
Statistical analysis
Results are expressed as percentages for categorical variables
and as mean 6 SD or median [quartiles] for continuous variables,
depending on whether or not the distribution was normal.
Percentages were compared using the chi-square test. To compare
continuous variables, Student t test for normally distributed
variables or Mann-Whitney test for variables without normal
distribution was conducted. ANOVA was used for comparison
among several quantitative variables. Pearson’s or Spearman
coefficients determined the bivariate correlation. Several models of
logistic regression analysis determined the influence of tempera-
ture on outcome at 3 months, after adjusting for those variables
that were statistically significant (p#0.05) in univariate analysis.
The results were expressed as adjusted odds ratios with a
confidence interval of 95%. Statistical analysis was conducted
using SPSS 16.0 for Macintosh.
Results
No differences in age (71.6613.9 vs. 72.4612.6 years,
p=0.316) or sex (male sex 62.8 vs. 58.1%, p=0.145) were found
between control group and patients.
Temperature in control group was 36.2560.41uC. Tempera-
tures in stroke patients were 36.3760.49uC on admission,
36.6660.62uC at 24 hours, 36.6760.57uC at 48 hours and
36.8760.56uC at 72 hours. All temperatures were significantly
higher than the previous one (p,0.0001 on admission in relation
with control group, p,0.0001 at 24 hours in relation to
admission, p=0.002 at 48 hours compared to 24 hours and
p,0.0001 at 72 hours in relation to 48 hours), as shown in
(Figure 1). High temperature was present in 9.4% of patients on
admission and this percentage increased over time (22.9% at
24 hours, 24.8% at 48 hours and 33.3% at 72 hours).
Correlation between axillary temperature and stroke severity
determined by the NIHSS was not demonstrated on admission
(Spearman coefficient=20.094, p=0.064), although a significant
correlation exists at 24 hours (Spearman coefficient=0.454,
p,0.0001) and at 48 hours (Spearman coefficient=0.334,
p,0.0001). This association disappears at 72 hours (Spearman
coefficient=0.040, p=0.103) (Figure 2).
Poor outcome at 3 months was observed in 1118 patients
(38.14%) and 361 patients died (12.31% of total). Patients with
poor outcome had significantly higher temperatures at every time
period analyzed (p,0.0001). The univariate analysis for outcome
at 3 months is shown in Table 1.
In logistic regression models, the effect of temperature was
determined as a continuous variable in the four periods of time in
relation to outcome at 3 months, adjusted for baseline variables
significant in univariate analysis (age, sex, hypertension, smoking,
atrial fibrillation, heart failure, previous TIA, anticoagulation, time
from symptom onset to admission, systolic blood pressure, glucose
levels, inflammation, NIHSS and temperature in every time
period analyzed). The analysis showed no association with the
basal body temperature (OR 1.10, 95% CI 0.98–5.13, p=0.087),
and with temperature at 72 hours (OR 0.98, 95% CI 0.76–1.26,
p=0.886), but an association was found at 24 hours (OR 2.05,
95% CI 1.59–2.64, p,0.0001) and 48 hours (OR 1.93, 95% CI
1.08–2.34, p=0.007).
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temperature at 24 and at 48 hours, and outcome. For patients
with IS (lacunar vs. non-lacunar), variables included were infarct
volume, use of thrombolytic therapy and inclusion in a clinical
trial. For patients with ICH, variables included were volume on
admission and inclusion in a clinical trial. A significant correlation
between temperature at 24 hours and outcome at 3 months was
found for patients with IS (OR 1.73, 95% CI 1.19–2.52, p=0.004)
and ICH (OR 2.16, 95% CI 1.14–4.01, p=0.018). At 48 hours, a
significant correlation still exists for patients with IS (OR 2.29,
95% CI 1.62–3.30, p=0.001) but not for those with an ICH (OR
1.47, 95% CI 0.23–3.94, p=0.133).
To analyze the possible neuroprotective effect of low temper-
ature, we determined the relationship between modifications of the
NIHSS score in every period compared to the previous ones. The
changes were only significant in the first 24 hours (NIHSS
24 hours - NIHSS on admission in the group of patients with
low basal temperature was 22[ 24, 0], in patients with normal
temperature 0 [21, 0] and in patients with high temperature 0
[21, 2], p,0.0001, Figure 3). In the group of patients with low
temperature, temperature at admission was significantly associated
with good outcome at 3 months (OR 0.84, 95% CI 0.50 to 0.94,
p,0.0001), but this association was not demonstrated at 24, 48 or
72 hours.
Among patients with basal high temperature, intercurrent
infection was detected in 0.7% of them on admission, 6.2% at
24 hours, 18.0% at 48 hours and 21.7% at 72 hours. The
presence of systemic infection was higher in the group of patients
with high temperature (.37 C) compared with any other groups
36–37 C and ,36 (p,0,0001) (Figure 4). In the subgroup of
patients with systemic inflammation, high temperature was
associated with poor outcome on admission (OR 2.17, 95% CI
1.10–4.69, p=0.009), at 24 hours (OR 4.43, 95% CI 1.36–6.68,
p,0.0001) and at 48 hours (OR 3.02, 95% CI 1.17–5.87,
p=0.001). Figure 5 shows the result of all multivariate models
analyzed.
Discussion
The most novel observations demonstrated in our study
are the following
1. Acute cerebrovascular disease is associated with
increased body temperature. Temperature rise is probably
due to brain injury and not to systemic complications, since it was
analyzed at 8 hours on average from stroke onset (including 16.4%
of patients who had a wake-up stroke). Differences in temperature
among patients and controls exist despite the fact that 16.3% of
the patients were previously taking antiplatelet therapy, mostly
aspirin. One limitation to this conclusion is that we used subjects
with a different risk factor profile as the control group, but the
differences were also significant in 2571 patients at 3 months
(36.2160.54uC, p,0.0001) compared to the temperature on
admission (data not shown previously), although at 3 months we
lost most severe patients for the analysis and 62.8% of patients
were taking antiplatelet agents.
Our data are consistent with experimental studies that show an
increase of pro-inflammatory cytokines and leukocytes surround-
ing the infarcted tissue [15], which may be responsible for
hypothalamic neuronal stimulation. Regional temperature in-
crease surrounding the infarcted area was also found using MRI
spectroscopy [16], although its relationship with outcome has not
been confirmed.
Figure 1. Normal distribution of temperatures in the control group and patients on admission and the maximum temperature in
the first 24 hours, between 24 and 48 hours, and between 48 and 72 hours.
doi:10.1371/journal.pone.0030700.g001
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neurogenic origin rather than systemic, is associated with large
lesions [17], no association between temperature on admission and
stroke severity (Figure 2), or volume of lesion was found (data not
shown). Therefore, this effect may be due to metabolic (potentially
modifiable) rather than structural mechanisms.
2. The therapeutic window for neuroprotection mediated
by hypothermia is shorter than 24 hours. In our study the
decrease in NIHSS score observed in the group of patients with
low temperature on admission is only evident in the first 24 hours,
and, in multivariate analysis, only temperature below 36uC was
independently associated with good outcome at 3 months.
In animal models, the ability of hypothermia to confer
neuroprotection was found to be directly dependent on the delay
of treatment initiation [18], and in clinical practice, prolonged
hypothermia is used because in most patients the decrease of
temperature is induced several hours after the stroke onset [19].
Two clinical trials in patients with cardiac arrest showed that when
hypothermia was started within 2 hours after the event, a
significant reduction in neurological deficit was obtained [20,21].
Our observation is also supported by experimental data. Many of
the mechanisms of neuroprotection associated with hypothermia,
particularly neurotoxicity and inflammation, appear minutes after
induction of ischemia and have a short duration [22].
In regard to optimal duration of hypothermia induction,
preclinical data have demonstrated that hypothermia for 48 hours
initiated 1 hour after permanent MCA occlusion in rats provided
better functional and morphologic outcomes than hypothermia for
24 or 12 hours, [23], therefore it would seem reasonable to think
that longer hypothermia time could induce better results, however,
to date there is no clear clinical evidence to demonstrate such
effects. Our data, in agreement with another recent clinical study
[11], show that the window for neuroprotection mediated
hypothermia is less than 24 hours. Our observations may be also
interesting for future clinical trials, since maintaining hypothermia
for several days increases patient discomfort and complications
derived from the process [24]. Under our opinion multiple factors
can determine the optimal duration of hypothermia in patients,
such as the severity of ischemia, occurrence of reperfusion, time of
the hypothermia induction after ischemia, risk of complication
because of hypothermia, etc [3]. One small phase II trial is
currently comparing the feasibility of cooling for 12 and 24 hours
Figure 2. Scatterplot and regression lines with CI 95% between NIHSS and axillary temperature at admission, 24, 48 and 72 hours.
The association between temperature and the severity of stroke is significant at 24 and 48 hours, but not on admission or at 72 hours.
doi:10.1371/journal.pone.0030700.g002
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Good outcome n=1813 Poor outcome n=1118 p
Age, years 70.7612.8 75.2611.7 ,0.0001
Male, % 63.5 49.3 ,0.0001
History of hypertension, % 39.5 45.2 0.003
History of diabetes, % 17.3 16.2 0.447
History of hyperlipidemia, % 22.2 21.1 0.490
Alcohol consumption, % 7.8 7.8 1.000
Tobacco consumption, % 11.4 8.1 0.004
Prior peripheral arterial disease, % 3.3 3.0 0.828
Prior coronary heart disease, % 7.6 8.8 0.265
Prior atrial fibrillation, % 10.3 16.8 ,0.0001
Prior heart failure, % 1.3 3.1 0.001
Prior carotid disease, % 0.3 0.1 0.417
Prior TIA, % 0.9 2.2 0.006
Prior antiplatelet treatment, % 15.6 17.5 0.165
Prior anticoagulant therapy, % 3.8 17.5 0.013
Latency time, hours (n=2325) 8.5610.1 7.467.8 ,0.0001
Axillary temperature on admission, uC (n=2931) 36.360.5 36.560.4 ,0.0001
Axillary temperature at 24 h, uC (n=2895) 36.460.5 36.960.7 ,0.0001
Axillary temperature at 48 h, uC (n=2842) 36.560.4 36.960.7 ,0.0001
Axillary temperature at 72 h, uC (n=2672) 36.860.4 36.960.7 ,0.0001
Axillary temperature on admission categorized ,0.0001
-Low, % (n=474) 19.4 11.0
-Normal, % (n=2160) 71.1 77.8
-High, % (n=297) 9.5 11.2
Axillary temperature at 24 hours categorized ,0.0001
-Low, % (n=564) 24.6 10.9
-Normal, % (n=1666) 67.0 41.8
-High, % (n=664) 8.4 47.3
Axillary temperature at 48 hours categorized ,0.0001
-Low, % (n=196) 5.6 9.2
-Normal, % (n=1941) 81.1 45.9
-High, % (n=704) 13.4 44.9
Axillary temperature at 72 hours categorized ,0.0001
-Low, % (n=133) 2.0 10.2
-Normal, % (n=1648) 71.2 45.1
-High, % (n=890) 26.8 44.8
Antipyretic treatmient during 48 hours, % 3.5 25.6 ,0.0001
Infection within 48 h, % 2.5 15.7 ,0.0001
NIHSS on admission (n=2931) 4 [2,6] 14 [7,18] ,0.0001
NIHSS at 24 h (n=2895) 3 [1,6] 14 [9,18] ,0.0001
NIHSS at 48 h (n=2843) 2 [0, 5] 13 [10,17] ,0.0001
NIHSS at 72 h (n=2701) 2 [0, 5] 13 [9,16] 0.115
Difference NIHSS 24 h2NIHSS 0 h 21[ 22, 0] 0 [0, 1] ,0.0001
Difference NIHSS 48 h2NIHSS 24 h 0 [22, 0] 0[21,0] ,0.0001
Difference NIHSS 72 h2NIHSS 48 h 0 [0, 0] 0 [0, 0] 0.115
SBP on admission, mm Hg (n=2931) 152.6627.6 154.1627.9 0.005
DBP on admission, mm Hg (n=2931) 82.7615.0 82.4616.6 0.487
Glucose on admission, mg/dL (n=2816) 139.3662.9 146.9663.4 0.001
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trialreg/admin/rctview.asp?TC=2616.
Another important consideration is that temperature on
admission that was associated with lower brain damage in our
study was between 34.6 and 36uC. This observation is in line with
those studies that show that temperatures between 35 and 35.5uC
are tolerable and safe in clinical practice, however there is clear
no evidence of greater efficacy with temperatures below 35uC
[6,25]. Some clinical studies have demonstrated the possibility to
achieve hypothermia between 33uCa n d3 5 uC [26,27,28] and
control a long lasting warming up [29] with the aim of increase
the neuroprotective efficacy of hypothermia. Unfortunately,
discomfort and shivering increase with lower temperatures, and
cooling to these levels generally requires sedation, mechanical
Good outcome n=1813 Poor outcome n=1118 p
Inflammation, % 13.9 51.3 ,0.0001
-Leukocyte count, 610
3/mL (n=2912) 8.162.6 9.863.1 ,0.0001
-Fibrinogen, mg/dL (n=2815) 433.6695.1 507.66123.9 ,0.0001
-High-sensitive C-reactive, mg/L (n=2611) 2.269.2 6.9622.9 ,0.0001
-Erythrocyte sedimentation rate, mm/h (2636) 19.9618.6 34.4625.8 ,0.0001
Type of stroke 0.029
-Ischemic stroke, % (n=2468) 85.4 82.3
-Intracerebral hemorrhage, % (n=463) 14.6 17.7
TOAST ,0.0001
-Aterotrombotic, % 27.1 25.4
-Cardioembolic, % 25.9 37.6
-Lacunar, % 16.9 5.9
-Undetermined, % 28.4 27.5
-Other, % 1.7 3.4
Non-lacunar vs lacunar stroke ,0.0001
-Non-lacunar, % 83.1 94.1
-Lacunar, % 16.9 5.9
Intracerebral hemorrhage 0.715
-Hypertensive, % 49.1 46.2
-Amyloid, % 10.9 13.2
-Antiplatelet/anticoagulant treatment, % 17.0 20.8
-Arteriovenous malformation, % 2.3 2.0
-Other, % 20.8 17.8
Infart volume at 48–72 h, mL (n=1407) 15.8631.3 62.9667.6 ,0.0001
morrhage volume on admission, mL (n=435) 23.7637.2 59.2662.7 ,0.0001
Thrombolytic therapy, % 3.8 6.7 0.001
Inclusion in clinical trial, % 5.8 9.6 ,0.0001
doi:10.1371/journal.pone.0030700.t001
Table 1. Cont.
Figure 3. Differences in NIHSS score every 24 hours in patients with low, normal and high temperatures. In patients with low
temperature (,366C) within 24 hours a significant decrease in the NIHSS is observed.
doi:10.1371/journal.pone.0030700.g003
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with the risk of eliminating the benefits of the hypothermia
treatment. Nowadays, a new clinical trial in progress (http://
public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID=7853) is
being conducted to find out if cooling patients to either 33uC
or 35uC, from a normal body temperature of around 37uC could
become a new treatment for reducing death and disability
following acute ischemic stroke.
3. The window to prevent brain damage mediated by
hyperthermia persists for at least 48 hours and is
associated with inflammatory mechanisms. This study
confirms previous findings [4,5,6,7,8,9,10,11,12] regarding the
association between hyperthermia and poor outcome in acute
cerebrovascular disease. However, this association is demonstrated
only after admission and during the first 48 hours. The
discrepancy between these data and those studies which find
association with temperature on admission [5,7,10] is probably
due to the shortening of latency between stroke onset and arrival at
hospital. In our study 32.9% of patients arrived within the first
3 hours and 53.8% within the first 6 hours after stroke onset, and
there was no relationship between NIHSS and temperature in
patients admitted within 3 hours (Spearman coefficient=20.007),
whereas a significant association exists for patients admitted to
hospital after 9 hours (Spearman coefficient=0.169, data not
shown). The PAIS study [12] analyzed patients admitted before
12 hours from stroke onset. In this study, the temperature on
admission was not associated with outcome, but temperature rise
in the following hours after admission was associated with poor
outcome, as it also happens in the VISTA study [11].
The presence of systemic inflammation significantly increases
the association between high temperatures and poor outcome, and
this association is also demonstrated with basal temperatures. This
aspect, which must be confirmed, may have clinical relevance for
selecting patients with high basal temperatures and inflammatory
response as candidates for more intensive antipyretic treatments or
even early hypothermic therapy. Systemic infection is associated
with high temperature only after 24 hours, but not during the first
hours after stroke onset.
The robust association of inflammation with hyperthermia and
poor outcome observed in our analysis explain why the blockade
of the inflammatory response is considered one of the most
important mechanisms associated with the beneficial effects of
hypothermia in ischemic stroke [31]. In addition, these data
confirm that blood levels of cytokines like TNF-a and IL-6 act as
good biomarkers of final infarct volume and early neurological
deterioration [32]
It is well established that after glia activation, increase of pro-
inflammatory cytokines and neutrophils appear within hours of
focal cerebral ischemia, peaking 1–2 days later in the rodent, and
are then replaced by monocytes/macrophages at 3–7 days.
Leukocytes enter injured tissue and contribute to secondary injury
by releasing reactive oxygen species (ROS), generating lipid
mediators, activating thrombosis, damaging the blood brain
barrier (BBB), increasing cerebral edema, and plugging the
cerebral microvasculature [15,33]. However this long temporal
profile does not explain why infection is associated with high
temperature mainly 24–48 h after stroke and why the therapeutic
window for neuroprotection mediated by hypothermia is less than
Figure 4. Patients with high temperatures (.376C) have more inflammation in all time periods analyzed.
doi:10.1371/journal.pone.0030700.g004
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inflammation on ischemic tissue. Besides the deleterious effect of
inflammation response, the phagocytic activity of activated
microglia and macrophages exerts beneficial effects in the long
term and may be necessary for tissue healing [31]. Therefore,
delayed hypothermia may adversely impact physiological condi-
tions on those processes necessary for tissue recovery such as
inflammation response.
4. Body temperature in relation to stroke outcome acts as
a continuous variable, uncategorized, both in ischemia and
ICH. Most of the published studies tend to categorize
temperature, considering hyperthermia from 37 to 38uC
[4,5,6,7,8,9,10,11,12], limiting the benefit of treatment for
patients with temperatures higher than the temperature
threshold. Our study demonstrates that temperature is a
continuous variable (see Figure 2) and its relationship with
outcome at 3 months is linear from 36.5uC, both in IS and in ICH
(Figure 6).
Although the strength of the association between temperature
and outcome is much higher for patients with IS, some studies
pointed out its influence on ICH. The temperature rise during the
first 24 hours is higher in ICH [12], and in animal models of brain
hemorrhage, hypothermia demonstrated benefit in relation to
brain edema reduction, but not to hematoma volume [34].
If our results are confirmed, an indication for antipyretic
treatment should start as soon as possible, both for IS and ICS,
starting with temperatures $36.5uC, with 36uC or below as a
therapeutic target.
5. Basal body temperature does not predict the efficacy of
thrombolytic therapy. In 121 patients treated with tPA
according to SITS-MOST criteria, the same benefit was obtained
in patients withlow, normal or high temperature at admission (good
outcome at 3 months: 65, 44 and 63%, p=0.087). However, the
persistence of high temperatures at 24 and 48 hours conditioned a
poor outcome at 3 months (84 and 75% respectively).
In vitro studies showed an increase in fibrinolytic activity at high
temperatures [35], and in a recent study in 111 patients treated
with tPA, high temperatures at admission were associated with a
better outcome [36]. These results have not been validated by
other studies [12,36,37], but have shown results similar to ours
[38].
As a result, basal body temperature should not condition the
administration of thrombolytic treatment, but in these patients, the
temperature control must be strict and temperature rise during the
first 48 hours should be avoided. In fact, recently we have
demonstrated that high body temperature ($37uC) is associated
with lack of recanalization, greater hypodensity volume and worse
outcome in stroke patients treated with tPA, and risk of
Figure 5. Odds ratio and confidence intervals 95% of all the groups analyzed.
doi:10.1371/journal.pone.0030700.g005
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24 hours but not at admission [38,39].
Our study has some strong points from the analysis of a large
group of non-selected patients treated according to international
guidelines protocols in a stroke unit with certificated staff.
Although this is the analysis of a database, the selection of the
variables and the statistical methods were designed and
approved prior to analysis of the results. No data in this study
was obtained secondarily to the findings. The main limitation of
our study comes from the method for determining the
temperature, the axillary temperature measurement requires
careful attention by the medical staff and this procedure is not
always followed.
In summary, the inherent limitations of recanalization proce-
dures, the failure of other neuroprotective therapies, and the
possibility to control temperature and other physiological variables
in all patients, make the control of temperature one of the most
successful treatments in patients with an acute cerebrovascular
event. The results of our study suggest that the influence of
temperature on brain damage is time-dependent. During the first
hours, hyperthermia is infrequent and is associated with
intracerebral –non-systemic- mechanisms, so its early control
may block the ischemic cascade and lead to neuroprotective
effects. Lowering the temperature below 36uC appears to have
significant benefits. In contrast, later high temperatures are
associated with inflammatory mechanisms and seem to have a
Figure 6. Modified Rankin scale at 3 months in relation to temperature intervals of 0.56C from 34.5 to 39.56C. The relationship is
similar for patients with ischemic stroke (striped columns) and intracerebral hemorrhage (dotted columns).
doi:10.1371/journal.pone.0030700.g006
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prevent the progression of brain damage.
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